0001140361-22-028206.txt : 20220804 0001140361-22-028206.hdr.sgml : 20220804 20220804162204 ACCESSION NUMBER: 0001140361-22-028206 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 14 CONFORMED PERIOD OF REPORT: 20220804 ITEM INFORMATION: Results of Operations and Financial Condition ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20220804 DATE AS OF CHANGE: 20220804 FILER: COMPANY DATA: COMPANY CONFORMED NAME: NU SKIN ENTERPRISES, INC. CENTRAL INDEX KEY: 0001021561 STANDARD INDUSTRIAL CLASSIFICATION: WHOLESALE-DRUGS PROPRIETARIES & DRUGGISTS' SUNDRIES [5122] IRS NUMBER: 870565309 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-12421 FILM NUMBER: 221136953 BUSINESS ADDRESS: STREET 1: 75 WEST CENTER ST STREET 2: ATTN: GREGORY BELLISTON CITY: PROVO STATE: UT ZIP: 84601 BUSINESS PHONE: 801-345-1000 MAIL ADDRESS: STREET 1: 75 WEST CENTER ST STREET 2: ATTN: GREGORY BELLISTON CITY: PROVO STATE: UT ZIP: 84601 FORMER COMPANY: FORMER CONFORMED NAME: NU SKIN ENTERPRISES INC DATE OF NAME CHANGE: 19980909 FORMER COMPANY: FORMER CONFORMED NAME: NU SKIN ASIA PACIFIC INC DATE OF NAME CHANGE: 19960919 8-K 1 brhc10040414_8k.htm FORM 8-K
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM 8-K

CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

 
August 4, 2022
  
 
Date of Report (Date of earliest event reported)
 

 
NU SKIN ENTERPRISES, INC.
  
 
(Exact name of registrant as specified in its charter)
 

Delaware
  
001-12421
  
87-0565309
(State or other jurisdiction of incorporation)
  
(Commission File Number)
 
(IRS Employer Identification Number)

 
75 West Center Street
Provo, Utah 84601
  
 
(Address of principal executive offices and zip code)
  

 
(801) 345-1000
  
 
(Registrant’s telephone number, including area code)
 

 
N/A
  
 
(Former name or former address, if changed since last report)
  

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
 
☐
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
 
☐
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
 
☐
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
 
☐
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4 (c))
 
Securities registered pursuant to Section 12(b) of the Act:
 
Title of each class
Trading Symbol(s)
Name of each exchange on which registered
Class A Common Stock, $.001 par value
NUS
New York Stock Exchange

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☐
 
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 2.02
Results of Operations and Financial Condition.

On August 4, 2022, Nu Skin Enterprises, Inc. (the “Company”) issued a press release announcing its financial results for the three- and six-month periods ended June 30, 2022, and certain other information. A copy of the press release is attached as Exhibit 99.1 to this report.

The information furnished pursuant to this Item 2.02 and Exhibit 99.1 shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), and shall not be deemed to be incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act except as shall be expressly set forth by specific reference in such filing.

Item 9.01
Financial Statements and Exhibits.

(d) Exhibits.

Nu Skin Enterprises’ press release dated August 4, 2022, regarding financial results for the three- and six-month periods ended June 30, 2022.
   
104
Cover Page Interactive Data File (embedded within the Inline XBRL document).

SIGNATURE
 
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
 
 
 NU SKIN ENTERPRISES, INC. 
 
(Registrant)
   
 
/s/ Mark H. Lawrence
  
 
Mark H. Lawrence
 
Chief Financial Officer
Date:  August 4, 2022
 


EX-99.1 2 brhc10040414_ex99-1.htm PRESS RELEASE DATED AUGUST 4, 2022
Exhibit 99.1


 FOR IMMEDIATE RELEASE

Nu Skin Enterprises Reports Second Quarter Financial Results

PROVO, Utah — Aug. 4, 2022 — Nu Skin Enterprises, Inc. (NYSE: NUS) today announced second quarter 2022 results.

Executive Summary
Q2 2022 vs. Prior-year Quarter

Revenue:
    
$560.6 million; (20)%
•    (5)% FX impact or $(34.6) million
Earnings Per Share (EPS):
    
$0.67 or $0.77 excluding charges associated with our Q4 2021 exit from Grow Tech, compared to $1.15 in Q2 2021
Customers:
    
1,380,615; (6)%
Paid Affiliates:
    
242,133; (16)%
Sales Leaders:
    
50,085; (24)%

“As previously announced, our second quarter results were impacted by extended COVID-related factors in Mainland China, distractions in EMEA related to the ongoing conflict, weaker global economic conditions impacting emerging markets and the record strength of the U.S. dollar,” said Ryan Napierski, Nu Skin president and CEO. “Despite these challenges, we delivered our ninth consecutive quarter of growth in the U.S. on the strength of new product launches and our social commerce model. Additionally, we drove year-over-year growth in our Southeast Asia/Pacific and Hong Kong/Taiwan segments due to the successful launch of ageLOC Meta and early social commerce adoption.

“Looking toward the balance of the year, we remain focused on Nu Vision 2025, including:
•
Introduction of EmpowerMe, our personalized beauty and wellness strategy, with the launch of our connected LumiSpa iO device beginning in the third quarter;
•
Expansion of affiliate-powered social commerce by introducing a new affiliate incentive structure known as ‘One Price’ beginning with LumiSpa iO and other select products; and
•
Further adoption of our recently introduced Vera and Stela apps with expanded languages and functionality, as well as the introduction of MyShop in China.

“Given the current landscape, we are taking aggressive measures to re-align our capabilities and resources with a focus on delivering Nu Vision 2025, which will result in a restructuring event in the second half and reduced operating expenses going forward. While we anticipate macro factors will continue to weigh on the business in the short-term, we remain confident in the direction and potential of our vision.”

Nu Skin Enterprises Reports Second Quarter Financial Results
page 2
Q2 2022 Year-over-year Operating Results

Revenue:
    
$560.6 million compared to $704.1 million
•    (5)% FX impact
Gross Margin:
    
73.6% compared to 75.6%
•    Impacted by product mix and foreign currency exchange
•    Nu Skin business was 77.0% compared to 78.3%
Selling Expenses:
    
39.1% compared to 39.9%
•    Nu Skin business was 42.0% compared to 42.8%
G&A Expenses:
    
25.3% compared to 23.6%
Operating Margin:
    
9.2% compared to 12.1%
Other Income / (Expense):
    
$(8.6) million or $(2.9) million excluding charges associated with our Q4 2021 exit from Grow Tech, compared to $(4.0) million
Income Tax Rate:
    
20.2% compared to 27.1%
EPS:
    
$0.67 or $0.77 excluding charges associated with our Q4 2021 exit from Grow Tech, compared to $1.15 in Q2 2021

Stockholder Value
Dividend Payments:
    
$19.4 million
Stock Repurchases:
    
$10.0 million
•     $225.4 million remaining in authorization

Q3 and Full-year 2022 Outlook
Q3 2022 Revenue:
    
$550 to $590 million; (13) to (8)%
•    Approximately (6)% FX impact
Q3 2022 EPS:
    
$0.04 to $0.22 or $0.70 to $0.85 non-GAAP
2022 Revenue:
    
$2.33 to $2.41 billion; (14) to (11)%
•    Approximately (5)% FX impact
2022 EPS:
    
$2.46 to $2.76 or $3.30 to $3.60 non-GAAP

“In light of the heightened global uncertainties and their impact on our business, we are adjusting our annual guidance,” added Mark Lawrence, chief financial officer. “Our 2022 revenue guidance is now expected to be $2.33 to $2.41 billion, with an approximate 5 percent foreign currency headwind. We anticipate reported EPS of $2.46 to $2.76 or $3.30 to $3.60 excluding the Q2 charges associated with our Q4 2021 exit from Grow Tech, as well as second half restructuring and impairment charges of $35 to $45 million associated with the strategic reallocation of our capabilities and resources toward Nu Vision 2025. We believe these actions will benefit the balance of 2022 and provide approximately $100 million in cost savings in 2023. For the third quarter, we project revenue of $550 to $590 million, assuming a negative foreign currency impact of approximately 6 percent, with reported earnings per share of $0.04 to $0.22 or $0.70 to $0.85 when excluding the third-quarter charge of approximately $30 million of the $35 to $45 million estimate.”

Nu Skin Enterprises Reports Second Quarter Financial Results
page 3
Conference Call
The Nu Skin Enterprises management team will host a conference call with the investment community today at 5 p.m. (ET). Those wishing to access the webcast, as well as the financial information presented during the call, can visit the Investor Relations page on the company's website at ir.nuskin.com. A replay of the webcast will be available on the same page through Aug. 18, 2022.
 
About Nu Skin Enterprises, Inc.
Nu Skin Enterprises, Inc. (NYSE: NUS) is a global integrated beauty and wellness company, powered by a dynamic affiliate opportunity platform. The company helps people look, feel and live their best with products that combine the best of science, technology and nature. Backed by more than 35 years of scientific research, Nu Skin develops innovative products including Nu Skin® personal care, Pharmanex® nutrition and the ageLOC® anti-aging brand which includes an award-winning line of beauty device systems. Nu Skin operates in approximately 50 markets worldwide in the Americas, Asia, Europe, Africa and the Pacific. Rhyz Inc. is the company’s strategic investment arm that includes a collection of technology and manufacturing companies to support growth in the core Nu Skin business. Nu Skin is committed to sustainability, including global initiatives such as transitioning to reduced and sustainable packaging for all products by 2030. The Nu Skin Force for Good Foundation also strives to improve children’s health, education and economic circumstances throughout the world. For more information, visit nuskin.com.
 
Nu Skin Enterprises Reports Second Quarter Financial Results
page 4
Important Information Regarding Forward-Looking Statements: This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, that represent the company’s current expectations and beliefs. All statements other than statements of historical fact are “forward-looking statements” for purposes of federal and state securities laws and include, but are not limited to, statements of management’s expectations regarding the company’s performance, growth, shareholder value, strategies, vision, transformation, initiatives, product pipeline and product introductions, digital and social-commerce tools and initiatives, customers, sales leaders, affiliates, and operational improvements; projections regarding revenue, expenses, operating income, earnings per share, foreign currency fluctuations, uses of cash and other financial items; statements of belief; and statements of assumptions underlying any of the foregoing. In some cases, you can identify these statements by forward-looking words such as “believe,” “expect,” “anticipate,” “project,” “outlook,” “guidance,” “remain,” “become,” “plan,” “potential,” “expand,” “will,” “would,” “could,” “may,” “might,” the negative of these words and other similar words.

The forward-looking statements and related assumptions involve risks and uncertainties that could cause actual results and outcomes to differ materially from any forward-looking statements or views expressed herein. These risks and uncertainties include, but are not limited to, the following:
•
risk that epidemics, including the ongoing COVID-19 pandemic, and other crises could negatively impact our business;
•
adverse publicity related to the company’s business, products, industry or any legal actions or complaints by the company’s sales force or others;
•
risk that direct selling laws and regulations in any of the company’s markets, including the United States and Mainland China, may be modified, interpreted or enforced in a manner that results in negative changes to the company’s business model or negatively impacts its revenue, sales force or business, including through the interruption of sales activities, loss of licenses, increased scrutiny of sales force actions, imposition of fines, or any other adverse actions or events;
•
any failure of current or planned initiatives or products to generate interest among the company’s sales force and customers and generate sponsoring and selling activities on a sustained basis;
•
political, legal, tax and regulatory uncertainties associated with operating in international markets, including Mainland China;
•
uncertainty regarding meeting restrictions and other government scrutiny in Mainland China, as well as negative media and consumer sentiment in Mainland China on our business operations and results;
•
risk of foreign-currency fluctuations and the currency translation impact on the company’s business associated with these fluctuations;
•
uncertainties regarding the future financial performance of the businesses the company has acquired;
•
risks related to accurately predicting, delivering or maintaining sufficient quantities of products to support planned initiatives or launch strategies, and increased risk of inventory write-offs if the company over-forecasts demand for a product or changes its planned initiatives or launch strategies;
•
regulatory risks associated with the company’s products, which could require the company to modify its claims or inhibit its ability to import or continue selling a product in a market if the product is determined to be a medical device or if the company is unable to register the product in a timely manner under applicable regulatory requirements;
•
unpredictable economic conditions and events globally, including trade policies and tariffs;
•
the company’s future tax-planning initiatives; any prospective or retrospective increases in duties on the company’s products imported into the company’s markets outside of the United States; and any adverse results of tax audits or unfavorable changes to tax laws in the company’s various markets; and
•
continued competitive pressures in the company’s markets.

The company’s financial performance and the forward-looking statements contained herein are further qualified by a detailed discussion of associated risks set forth in the documents filed by the company with the Securities and Exchange Commission. The forward-looking statements set forth the company’s beliefs as of the date that such information was first provided, and the company assumes no duty to update the forward-looking statements contained in this release to reflect any change except as required by law.

Nu Skin Enterprises Reports Second Quarter Financial Results
page 5
Non-GAAP Financial Measures: Constant-currency revenue change is a non-GAAP financial measure that removes the impact of fluctuations in foreign-currency exchange rates, thereby facilitating period-to-period comparisons of the company’s performance. It is calculated by translating the current period’s revenue at the same average exchange rates in effect during the applicable prior-year period and then comparing that amount to the prior-year period’s revenue. The company believes that constant-currency revenue change is useful to investors, lenders and analysts because such information enables them to gauge the impact of foreign-currency fluctuations on the company’s revenue from period to period.

Earnings per share and other income (expense), each excluding restructuring and impairment charges and/or charges associated with our Grow Tech exit, also are non-GAAP financial measures. Restructuring and impairment charges and charges associated with our Grow Tech exit are not part of the ongoing operations of our underlying business. The company believes that these non-GAAP financial measures are useful to investors, lenders and analysts because removing the impact of restructuring and impairment charges and charges associated with our Grow Tech exit facilitates period-to-period comparisons of the company’s performance. Please see the reconciliations of these items to our earnings per share and other income (expense) calculated under GAAP, below.

The following table sets forth revenue for the three-month periods ended June 30, 2022 and 2021 for each of our reportable segments (U.S. dollars in thousands):

   
Three Months Ended
June 30,
    
Change
      
Constant-
Currency
Change
   
   
2022
    
2021
    
Nu Skin
                        
Americas
  
$
124,445
    
$
138,512
      
(10
)%
    
(9
)%
Mainland China
    
86,808
      
154,182
      
(44
)%
    
(42
)%
Southeast Asia/Pacific
    
94,067
      
83,968
      
12
%
    
16
%
South Korea
    
69,308
      
88,604
      
(22
)%
    
(12
)%
Japan
    
55,952
      
68,020
      
(18
)%
    
(3
)%
EMEA
    
50,871
      
83,115
      
(39
)%
    
(31
)%
Hong Kong/Taiwan
    
39,327
      
38,529
      
2
%
    
6
%
Nu Skin other
    
1,318
      
947
      
39
%
    
39
%
Total Nu Skin
    
522,096
      
655,877
      
(20
)%
    
(15
)%
Rhyz Investments
                                
Manufacturing
    
38,229
      
48,140
      
(21
)%
    
(21
)%
Rhyz other
    
290
      
38
      
663
%
    
663
%
Total Rhyz Investments
    
38,519
      
48,178
      
(20
)%
    
(20
)%
Total
  
$
560,615
    
$
704,055
      
(20
)%
    
(15
)%

The following table sets forth revenue for the six-month periods ended June 30, 2022 and 2021 for each of our reportable segments (U.S. dollars in thousands):

   
Six Months Ended
June 30,
    
Change
      
Constant-
Currency
Change
   
   
2022
    
2021
    
Nu Skin
                        
Americas
  
$
248,025
    
$
272,273
      
(9
)%
    
(8
)%
Mainland China
    
211,303
      
303,775
      
(30
)%
    
(31
)%
Southeast Asia/Pacific
    
184,303
      
167,257
      
10
%
    
14
%
South Korea
    
141,441
      
169,735
      
(17
)%
    
(8
)%
Japan
    
117,743
      
137,884
      
(15
)%
    
(3
)%
EMEA
    
103,839
      
159,295
      
(35
)%
    
(28
)%
Hong Kong/Taiwan
    
77,821
      
74,874
      
4
%
    
6
%
Nu Skin other
    
1,938
      
1,825
      
6
%
    
6
%
Total Nu Skin
    
1,086,413
      
1,286,918
      
(16
)%
    
(12
)%
Rhyz Investments
                                
Manufacturing
    
78,570
      
94,125
      
(17
)%
    
(17
)%
Rhyz other
    
531
      
38
      
1,297
%
    
1,297
%
Total Rhyz Investments
    
79,101
      
94,163
      
(16
)%
    
(16
)%
Total
  
$
1,165,514
    
$
1,381,081
      
(16
)%
    
(12
)%

Nu Skin Enterprises Reports Second Quarter Financial Results
page 6
The following table provides information concerning the number of Customers, Paid Affiliates and Sales Leaders in our core Nu Skin business for the three-month periods ended June 30, 2022 and 2021:

   
Three Months Ended
June 30,
    
Change
   
Customers
  
2022
    
2021
    
Americas
    
302,849
      
368,052
      
(18
)%
Mainland China
  
$
392,268
      
328,526
      
19
%
Southeast Asia/Pacific
    
152,775
      
165,221
      
(8
)%
South Korea
    
135,290
      
153,282
      
(12
)%
Japan
    
122,643
      
125,734
      
(2
)%
EMEA
    
205,379
      
261,881
      
(22
)%
Hong Kong/Taiwan
    
69,411
      
64,861
      
7
%
Total
    
1,380,615
      
1,467,557
      
(6
)%

   
Three Months Ended
June 30,
    
Change
   
Paid Affiliates
  
2022
    
2021
    
Americas
    
44,523
      
53,492
      
(17
)%
Mainland China
  
$
19,257
      
39,889
      
(52
)%
Southeast Asia/Pacific
    
41,512
      
44,734
      
(7
)%
South Korea
    
48,605
      
52,680
      
(8
)%
Japan
    
38,269
      
38,623
      
(1
)%
EMEA
    
32,323
      
42,682
      
(24
)%
Hong Kong/Taiwan
    
17,644
      
17,815
      
(1
)%
Total
    
242,133
      
289,915
      
(16
)%

   
Three Months Ended
June 30,
    
Change
   
Sales Leaders
  
2022
    
2021
    
Americas
    
9,320
      
11,752
      
(21
)%
Mainland China
  
$
11,458
      
20,946
      
(45
)%
Southeast Asia/Pacific
    
8,407
      
8,190
      
3
%
South Korea
    
6,557
      
7,701
      
(15
)%
Japan
    
6,097
      
6,057
      
1
%
EMEA
    
5,192
      
8,002
      
(35
)%
Hong Kong/Taiwan
    
3,054
      
3,446
      
(11
)%
Total
    
50,085
      
66,094
      
(24
)%

“Customers” are persons who have purchased directly from the Company during the three months ended as of the date indicated. Our Customer numbers include members of our sales force who made such a purchase, including Paid Affiliates and those who qualify as Sales Leaders, but they do not include consumers who purchase products directly from members of our sales force.

“Paid Affiliates” are any Brand Affiliates, as well as sales employees and independent marketers in Mainland China, who earned sales compensation during the three-month period. In all of our markets besides Mainland China, we refer to members of our independent sales force as “Brand Affiliates” because their primary role is to promote our brand and products through their personal social networks.

“Sales Leaders” are the three-month average of our monthly Brand Affiliates, as well as sales employees and independent marketers in Mainland China, who had achieved certain qualification requirements as of the end of each month of the quarter.
Nu Skin Enterprises Reports Second Quarter Financial Results
page 7
NU SKIN ENTERPRISES, INC.
Consolidated Statements of Income (Unaudited)
(U.S. dollars in thousands, except per share amounts)

   
Three Months Ended
June 30,
    
Six Months Ended
June 30,
  
   
2022
    
2021
    
2022
    
2021
  
Revenue
  
$
560,615
    
$
704,055
    
$
1,165,514
    
$
1,381,081
  
Cost of sales
    
148,100
      
171,975
      
309,599
      
342,541
  
Gross profit
    
412,515
      
532,080
      
855,915
      
1,038,540
  
                                 
Operating expenses:
                                
Selling expenses
    
219,426
      
280,589
      
462,125
      
556,554
  
General and administrative expenses
    
141,562
      
166,115
      
290,118
      
333,697
  
Total operating expenses
    
360,988
      
446,704
      
752,243
      
890,251
  
                                 
Operating income
    
51,527
      
85,376
      
103,672
      
148,289
  
Other income (expense), net
    
(8,640
)
    
(4,012
)
    
(10,093
)
    
(2,430
)
                                 
Income before provision for income taxes
    
42,887
      
81,364
      
93,579
      
145,859
  
Provision for income taxes
    
8,650
      
22,026
      
20,626
      
39,091
  
                                 
Net income
  
$
34,237
    
$
59,338
    
$
72,953
    
$
106,768
  
                                 
Net income per share:
                                
Basic
  
$
0.68
    
$
1.18
    
$
1.45
    
$
2.12
  
Diluted
  
$
0.67
    
$
1.15
    
$
1.43
    
$
2.06
  
                                 
Weighted-average common shares outstanding (000s):
                                
Basic
    
50,368
      
50,115
      
50,181
      
50,409
  
Diluted
    
50,960
      
51,557
      
50,959
      
51,850
  

Nu Skin Enterprises Reports Second Quarter Financial Results
page 8
NU SKIN ENTERPRISES, INC.
Consolidated Balance Sheets (Unaudited)
(U.S. dollars in thousands)

   
June 30,
2022
    
December 31,
2021
  
ASSETS
            
Current assets:
            
Cash and cash equivalents
  
$
363,923
    
$
339,593
  
Current investments
    
17,877
      
15,221
  
Accounts receivable, net
    
43,694
      
41,299
  
Inventories, net
    
354,211
      
399,931
  
Prepaid expenses and other
    
103,188
      
76,906
  
Total current assets
    
882,893
      
872,950
  
                 
Property and equipment, net
    
443,036
      
453,674
  
Operating lease right-of-use assets
    
118,413
      
120,973
  
Goodwill
    
206,432
      
206,432
  
Other intangible assets, net
    
72,665
      
76,991
  
Other assets
    
177,462
      
175,460
  
Total assets
  
$
1,900,901
    
$
1,906,480
  
                 
LIABILITIES AND STOCKHOLDERS’ EQUITY
                
Current liabilities:
                
Accounts payable
  
$
55,013
    
$
49,993
  
Accrued expenses
    
289,130
      
372,201
  
Current portion of long-term debt
    
40,000
      
107,500
  
Total current liabilities
    
384,143
      
529,694
  
                 
Operating lease liabilities
    
90,156
      
88,759
  
Long-term debt
    
387,179
      
268,781
  
Other liabilities
    
98,388
      
106,474
  
Total liabilities
    
959,866
      
993,708
  
                 
Commitments and contingencies
                
                 
Stockholders’ equity:
                
Class A common stock – 500 million shares authorized, $0.001 par value, 90.6 million shares issued
    
91
      
91
  
Additional paid-in capital
    
606,349
      
601,703
  
Treasury stock, at cost – 39.9 million and 40.7 million shares
    
(1,520,769
)
    
(1,526,860
)
Accumulated other comprehensive loss
    
(90,638
)
    
(73,896
)
Retained earnings
    
1,946,002
      
1,911,734
  
Total stockholders' equity
    
941,035
      
912,772
  
Total liabilities and stockholders’ equity
  
$
1,900,901
    
$
1,906,480
  

Nu Skin Enterprises Reports Second Quarter Financial Results
page 9
NU SKIN ENTERPRISES, INC.
Reconciliation of Earnings Per Share Excluding Charges Associated with Our Q4 2021
Exit from Grow Tech to GAAP Earnings Per Share
(in thousands, except per share amounts)
 
   
Three Months Ended
June 30, 2022
  
       
Net income
  
$
34,237
  
Impact of charges associated with our Q4 2021 exit from Grow Tech:
        
Unrealized investment loss
    
5,711
  
Income tax impact
    
(459
)
Adjusted net income
  
$
39,489
  
         
Diluted earnings per share
  
$
0.67
  
Diluted earnings per share, excluding charges associated with our Q4 2021 exit from Grow Tech
  
$
0.77
  
         
Weighted-average common shares outstanding (000s):
    
50,960
  
 
NU SKIN ENTERPRISES, INC.
Reconciliation of Other Income (Expense), Net Excluding Charges Associated with Our Q4 2021 Exit from Grow Tech to GAAP Other Income (Expense), Net
(in thousands)
 
   
Three Months Ended
June 30, 2022
  
       
Other income (expense), net
  
$
(8,640
)
Impact of charges associated with our Q4 2021 exit from Grow Tech:
        
Unrealized investment loss
    
5,711
  
Adjusted Other income (expense), net
  
$
(2,929
)
 
NU SKIN ENTERPRISES, INC.
Reconciliation of Earnings Per Share Excluding Certain Charges to GAAP Earnings Per Share
 
   
Three Months Ended
September 30, 2022
    
Year Ended
December 31, 2022
  
   
Low End
    
High End
    
Low End
    
High End
  
                         
Earnings per share
  
$
0.04
    
$
0.22
    
$
2.46
    
$
2.76
  
Impact of charges associated with our second half restructuring and impairment charges:
                                
Restructuring and Impairment
    
0.59
      
0.59
      
0.88
      
0.88
  
Income tax impact
    
0.07
      
0.04
      
(0.13
)
    
(0.13
)
Impact of charges associated with our Q4 2021 exit from Grow Tech:
                                
Unrealized investment loss
    
—
      
—
      
0.11
      
0.11
  
Income tax impact
    
—
      
—
      
(0.02
)
    
(0.02
)
Adjusted Earnings per share
  
$
0.70
    
$
0.85
    
$
3.30
    
$
3.60
  

# # #
CONTACTS:
Media: media@nuskin.com, (801) 345-6397
Investors: investorrelations@nuskin.com, (801) 345-3577


 EX-101.SCH 3 nus-20220804.xsd XBRL TAXONOMY EXTENSION SCHEMA 000100 - Document - Document and Entity Information link:presentationLink link:calculationLink link:definitionLink EX-101.LAB 4 nus-20220804_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Cover [Abstract] Document Type Written Communications Soliciting Material Pre-commencement Tender Offer Pre-commencement Issuer Tender Offer Amendment Flag Document Fiscal Year Focus Document Fiscal Period Focus Document Period End Date Entity Registrant Name Entity Central Index Key Entity File Number Entity Tax Identification Number Entity Incorporation, State or Country Code Entity Emerging Growth Company Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Three Entity Address, City or Town Entity Address, State or Province Entity Address, Country Entity Address, Postal Zip Code City Area Code Local Phone Number Title of 12(b) Security No Trading Symbol Flag Trading Symbol Security Exchange Name EX-101.PRE 5 nus-20220804_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE GRAPHIC 6 image0.jpg begin 644 image0.jpg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htm IDEA: XBRL DOCUMENT v3.22.2
Document and Entity Information
Aug. 04, 2022
Cover [Abstract]  
Document Type 8-K
Amendment Flag false
Document Period End Date Aug. 04, 2022
Entity File Number 001-12421
Entity Registrant Name NU SKIN ENTERPRISES, INC.
Entity Central Index Key 0001021561
Entity Incorporation, State or Country Code DE
Entity Tax Identification Number 87-0565309
Entity Address, Address Line One 75 West Center Street
Entity Address, City or Town Provo
Entity Address, State or Province UT
Entity Address, Postal Zip Code 84601
City Area Code 801
Local Phone Number 345-1000
Entity Emerging Growth Company false
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Title of 12(b) Security Class A Common Stock, $.001 par value
Trading Symbol NUS
Security Exchange Name NYSE
XML 8 brhc10040414_8k_htm.xml IDEA: XBRL DOCUMENT 0001021561 2022-08-04 2022-08-04 false 0001021561 8-K 2022-08-04 NU SKIN ENTERPRISES, INC. DE 001-12421 87-0565309 75 West Center Street Provo UT 84601 801 345-1000 false false false false Class A Common Stock, $.001 par value NUS NYSE false EXCEL 9 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 10 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 11 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 12 FilingSummary.xml IDEA: XBRL DOCUMENT 3.22.2 html 1 22 1 false 0 0 false 0 false false R1.htm 000100 - Document - Document and Entity Information Sheet http://nuskin.com/role/DocumentAndEntityInformation Document and Entity Information Cover 1 false false All Reports Book All Reports brhc10040414_8k.htm brhc10040414_ex99-1.htm nus-20220804.xsd nus-20220804_lab.xml nus-20220804_pre.xml http://xbrl.sec.gov/dei/2022 true false JSON 14 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "brhc10040414_8k.htm": { "axisCustom": 0, "axisStandard": 0, "contextCount": 1, "dts": { "inline": { "local": [ "brhc10040414_8k.htm" ] }, "labelLink": { "local": [ "nus-20220804_lab.xml" ] }, "presentationLink": { "local": [ "nus-20220804_pre.xml" ] }, "schema": { "local": [ "nus-20220804.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2004/ref-2004-08-10.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-roles-2022.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-types-2022.xsd", "https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd", "https://xbrl.fasb.org/us-gaap/2022/elts/us-roles-2022.xsd", "https://xbrl.fasb.org/us-gaap/2022/elts/us-types-2022.xsd", "https://xbrl.sec.gov/country/2022/country-2022.xsd", "https://xbrl.sec.gov/currency/2022/currency-2022.xsd", "https://xbrl.sec.gov/dei/2022/dei-2022.xsd", "https://xbrl.sec.gov/exch/2022/exch-2022.xsd", "https://xbrl.sec.gov/naics/2022/naics-2022.xsd", "https://xbrl.sec.gov/sic/2022/sic-2022.xsd", "https://xbrl.sec.gov/stpr/2022/stpr-2022.xsd" ] } }, "elementCount": 29, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2022": 2, "total": 2 }, "keyCustom": 0, "keyStandard": 22, "memberCustom": 0, "memberStandard": 0, "nsprefix": "nus", "nsuri": "http://nuskin.com/20220804", "report": { "R1": { "firstAnchor": { "ancestors": [ "div", "div", "div", "body", "html" ], "baseRef": "brhc10040414_8k.htm", "contextRef": "c20220804to20220804", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "000100 - Document - Document and Entity Information", "role": "http://nuskin.com/role/DocumentAndEntityInformation", "shortName": "Document and Entity Information", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "div", "body", "html" ], "baseRef": "brhc10040414_8k.htm", "contextRef": "c20220804to20220804", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 0, "tag": { "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://nuskin.com/role/DocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://nuskin.com/role/DocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2022", "xbrltype": "stringItemType" }, "dei_DocumentFiscalPeriodFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.", "label": "Document Fiscal Period Focus" } } }, "localname": "DocumentFiscalPeriodFocus", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://nuskin.com/role/DocumentAndEntityInformation" ], "xbrltype": "fiscalPeriodItemType" }, "dei_DocumentFiscalYearFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.", "label": "Document Fiscal Year Focus" } } }, "localname": "DocumentFiscalYearFocus", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://nuskin.com/role/DocumentAndEntityInformation" ], "xbrltype": "gYearItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://nuskin.com/role/DocumentAndEntityInformation" ], "xbrltype": "dateItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://nuskin.com/role/DocumentAndEntityInformation" ], "xbrltype": "submissionTypeItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://nuskin.com/role/DocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine2": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 2 such as Street or Suite number", "label": "Entity Address, Address Line Two" } } }, "localname": "EntityAddressAddressLine2", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://nuskin.com/role/DocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine3": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 3 such as an Office Park", "label": "Entity Address, Address Line Three" } } }, "localname": "EntityAddressAddressLine3", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://nuskin.com/role/DocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://nuskin.com/role/DocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCountry": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "ISO 3166-1 alpha-2 country code.", "label": "Entity Address, Country" } } }, "localname": "EntityAddressCountry", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://nuskin.com/role/DocumentAndEntityInformation" ], "xbrltype": "countryCodeItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://nuskin.com/role/DocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://nuskin.com/role/DocumentAndEntityInformation" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://nuskin.com/role/DocumentAndEntityInformation" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://nuskin.com/role/DocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://nuskin.com/role/DocumentAndEntityInformation" ], "xbrltype": "fileNumberItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://nuskin.com/role/DocumentAndEntityInformation" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://nuskin.com/role/DocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://nuskin.com/role/DocumentAndEntityInformation" ], "xbrltype": "employerIdItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://nuskin.com/role/DocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_NoTradingSymbolFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a security having no trading symbol.", "label": "No Trading Symbol Flag" } } }, "localname": "NoTradingSymbolFlag", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://nuskin.com/role/DocumentAndEntityInformation" ], "xbrltype": "trueItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r3" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre-commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://nuskin.com/role/DocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r4" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre-commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://nuskin.com/role/DocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r0" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://nuskin.com/role/DocumentAndEntityInformation" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://nuskin.com/role/DocumentAndEntityInformation" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://nuskin.com/role/DocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://nuskin.com/role/DocumentAndEntityInformation" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r6" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://nuskin.com/role/DocumentAndEntityInformation" ], "xbrltype": "booleanItemType" } }, "unitCount": 0 } }, "std_ref": { "r0": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b" }, "r1": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r2": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1" }, "r3": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c" }, "r4": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b" }, "r5": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12" }, "r6": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425" } }, "version": "2.1" } ZIP 15 0001140361-22-028206-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001140361-22-028206-xbrl.zip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end